Across TCGA pan-cancer cohorts, ZNF580 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ZNF580 data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in esophageal carcinoma (ESCA), where higher ZNF580 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF580 expression acts as an unfavorable survival marker.
ESCA are the cancer types where ZNF580 Mutation most reproducibly stratifies survival.